ABBV vs PANW: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Palo Alto Networks, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-26.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
Palo Alto Networks, Inc. · Technology
$374.74
-5.2% upside to fair value
Med Conviction
Grade C
High Quality
QuantHub Verdict
ABBV has more upside to fair value
(-1.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
PANW |
| Current Price |
$261.70 |
$374.74 |
| Fair Value Estimate |
$259.04 |
$355.11 |
| Upside to Fair Value |
-1.0%
|
-5.2%
|
| Market Cap |
$462.4B |
$305.4B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
569.8x
|
| Price / Sales |
7.2x
|
26.6x
|
| Price / FCF |
23.6x
|
64.0x
|
| Revenue Growth YoY |
+10.2%
|
+34.4%
|
| Gross Margin |
71.5%
|
70.4%
|
| Operating Margin |
29.3%
|
6.1%
|
| Return on Equity |
-136.5%
|
1.7%
|
| Dividend Yield |
2.61% |
0% |
| FCF Yield |
4.25%
|
1.56%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
Palo Alto Networks is a global cybersecurity leader built around next-generation firewalls, the Panorama management platform, and a broad subscription portfolio spanning threat prevention, cloud security, secure access, and security analytics, sold to medium and large enterprises, service providers, and governments through direct and channel distribution. The business quality is genuinely high on…
Accumulation Zones
| Metric |
ABBV |
PANW |
| Zone Low |
$194.28 |
$266.33 |
| Zone High |
$220.18 |
$301.84 |
| In Buy Zone? |
No
|
No
|